Related Experiment Videos

Endotoxin shock and tumour necrosis factor release in mannoheptulose-treated mice

Y M Choy1, C P Cheng, L U Luey

  • 1Department of Biochemistry, Chinese University of Hong Kong, Shatin.

Cancer Letters
|October 1, 1987
PubMed

Insights

Mannoheptulose protected mice against lethal endotoxin effects after Listeria infection, without impacting tumor necrosis factor production. It also reversed endotoxin-induced hypoglycemia, suggesting therapeutic potential.

Area of Science:

  • Immunology
  • Endocrinology
  • Microbiology

Background:

  • Listeria monocytogenes infection can lead to severe complications.
  • Endotoxins trigger significant physiological responses, including lethal effects and hypoglycemia.
  • Tumor necrosis factor (TNF) plays a role in the immune response to infection and endotoxins.

Purpose of the Study:

  • To investigate the protective effects of mannoheptulose in a mouse model of Listeria monocytogenes infection followed by endotoxin challenge.
  • To assess the impact of mannoheptulose on tumor necrosis factor production in infected mice.
  • To determine if mannoheptulose can mitigate the hypoglycemic effects of endotoxin.

Main Methods:

  • Mice infected with Listeria monocytogenes were administered mannoheptulose.
  • A subsequent challenge with endotoxin was administered to assess survival rates.
  • Tumor necrosis factor production was measured.
  • Blood glucose levels were monitored to evaluate hypoglycemic effects.

Main Results:

  • Mannoheptulose administration conferred partial protection against the lethal effects of endotoxin challenge in Listeria-infected mice.
  • Tumor necrosis factor production remained unaffected by mannoheptulose treatment.
  • Mannoheptulose reversed the hypoglycemia induced by endotoxin.
  • Inhibition of insulin secretion is proposed as a mechanism for the observed reversal of hypoglycemia.

Conclusions:

  • Mannoheptulose demonstrates partial therapeutic efficacy in mitigating lethal endotoxin effects post-Listeria infection.
  • The compound's ability to reverse endotoxin-induced hypoglycemia warrants further investigation for potential clinical applications.
  • Mannoheptulose does not appear to modulate TNF-alpha production in this model.

Related Concept Videos